An Open-label, Randomized, Cross-over Study With 2 Treatments (Fasting and After Meals), 3 Periods, 2 Sequences, and an Adaptive, Two-stage Design to Evaluate the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets at a Single Dose in Healthy Volunteers
Latest Information Update: 31 Jul 2023
At a glance
- Drugs XC-221 (Primary)
- Indications COVID 2019 infections; Influenza virus infections; Respiratory tract infections
- Focus Pharmacokinetics
- Sponsors Valenta Pharmaceuticals
Most Recent Events
- 25 Jul 2023 Status changed from recruiting to completed.
- 29 Mar 2022 New trial record